456 Studies Now Enrolling
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Study of Drug VK2809 in Patients with Primary Hypercholesterolemia and Non-Alcoholic Fatty Livery Disease
| Sponsor: | Viking Therapeutics, Inc. |
| Enrolling: | Male and Female Patients |
| Study Length: | 16 Weeks |
| IRB Number: | AAAR5964 |
| U.S. Govt. ID: | NCT02927184 |
| Contact: | Ali Andre Mencin MD: 212-305-5903 / am2363@cumc.columbia.edu |
Additional Study Information:
This study is a multicenter study to assess the efficacy, safety, and tolerability of vk2809 administered for12 weeks followed by a 4-week off-drug Phase in subjects with primary hypercholesterolemia and nonalcoholic Fatty liver disease. This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver disease. The primary efficacy endpoint is percent change from baseline LDL-C at the end of the treatment period (Week 12).
This study is closed
